Malignancy-associated dermatomyositis: Retrospective case–control study from a single tertiary care center - 18/06/18
Doi : 10.1016/j.jaad.2018.01.002
Laura Kooistra, BS a, Claudia Ricotti, BS b, Fabrizio Galimberti, MD c, Carmen Gota, MD d, Anthony P. Fernandez, MD, PhD e, f, ⁎ 
a Case Western Reserve University College of Medicine, Cleveland, Ohio
b University of Cincinnati College of Medicine, Cincinnati, Ohio
c University of Miami Department of Dermatology and Cutaneous Surgery, Miami, Florida
d Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio
e Department of Dermatology, Cleveland Clinic, Cleveland, Ohio
f Department of Pathology, Cleveland Clinic, Cleveland, Ohio
∗Correspondence to: Anthony P. Fernandez, MD, PhD, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Departments of Dermatology and Pathology, 9500 Euclid Ave, A61, Cleveland, OH 44195Cleveland Clinic Lerner College of Medicine, Cleveland ClinicDepartments of Dermatology and Pathology9500 Euclid Ave, A61ClevelandOH44195
| Funding sources: None. |
|
| Conflicts of interest: Dr Fernandez receives funding from Mallinckrodt for dermatomyositis research, is a consultant for AbbVie, and a speaker for AbbVie and Celgene. Other authors have no conflicts of interest to report. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 1
P. 152-155 - juillet 2018 Retour au numéro
Article précédent
- Cross-sectional assessment of ultraviolet radiation–related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma
- Leah M. Ferrucci, Brenda Cartmel, Rachel A. Clare, Courtney C. Choy, Trace Kershaw, David J. Leffell, Susan T. Mayne
- Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies
- Jorge R. Georgakopoulos, Michelle Phung, Arvin Ighani, Jensen Yeung
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?